WO2023008129A1 - 検査用カートリッジ - Google Patents

検査用カートリッジ Download PDF

Info

Publication number
WO2023008129A1
WO2023008129A1 PCT/JP2022/026937 JP2022026937W WO2023008129A1 WO 2023008129 A1 WO2023008129 A1 WO 2023008129A1 JP 2022026937 W JP2022026937 W JP 2022026937W WO 2023008129 A1 WO2023008129 A1 WO 2023008129A1
Authority
WO
WIPO (PCT)
Prior art keywords
amplification
inspection
liquid
area
amplification liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/026937
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
威史 濱
裕康 石井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Priority to EP22849194.0A priority Critical patent/EP4379380A4/en
Priority to JP2023538386A priority patent/JPWO2023008129A1/ja
Publication of WO2023008129A1 publication Critical patent/WO2023008129A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody

Definitions

  • the present disclosure relates to inspection cartridges.
  • Patent Documents 1 and 2 describe an immunochromatography kit for testing whether a specimen is positive or negative, that is, whether or not a specimen contains a test substance, using immunochromatography.
  • This immunochromatography kit is called an inspection cartridge or the like.
  • the immunochromatography kits described in Patent Documents 1 and 2 include a specimen, a test strip supplied with a reagent such as an amplification solution, and a case containing the test strip.
  • the test strip has a test area on which an antibody that specifically binds to an antigen, which is a test substance, is immobilized.
  • an antibody that specifically binds to an antigen which is a test substance
  • the antigen binds to the antibody immobilized in the test area, and the labeled substance is captured via the antigen. be done. If the amount of labeling substance captured in this inspection area is very small, the color development is weak and may be determined as a false negative.
  • an amplification solution is supplied to the inspection area in order to amplify the color development of the inspection area by the labeling substance.
  • a storage section is provided in the case to store an amplification liquid, and the amplification liquid is supplied from the storage section to the test strip and spread toward the test area.
  • the amplification liquid soaks into the test strip and is developed toward the test area by the capillary force of the test strip, and may also flow toward the test area on the surface of the test strip. Foaming may occur in the amplification fluid, and foaming is particularly noticeable when the amplification fluid flows over the surface of the test strip. Bubbles in the amplification solution become noise when determining the coloring state of the inspection area. Therefore, in order to make an accurate judgment in the inspection, it was necessary to wait until the bubbles disappeared. The amplification liquid retreats from the inspection area over time, and the bubbles also disappear. However, if the time until the bubbles disappear is long, there is a problem that the throughput of the inspection is lowered.
  • An object of the present invention is to provide an inspection cartridge capable of improving throughput.
  • the test cartridge of the present disclosure is a test cartridge used for immunochromatographic testing, a test strip having on its surface a test area whose coloring state changes depending on whether the sample is positive or negative; a storage unit that stores an amplification liquid that amplifies the color development of the test area; and an antifoaming agent that eliminates bubbles generated in the amplification liquid.
  • the antifoaming agent may be contained in the amplification liquid.
  • the amplification liquid includes a first amplification liquid and a second amplification liquid, and the first amplification liquid and the second amplification liquid are reacted on the test strip to develop a color in the test area.
  • the storage section preferably includes a first storage section that stores the first amplification liquid and a second storage section that stores the second amplification liquid.
  • the antifoaming agent when the amplifying liquid is of the two-liquid type, the antifoaming agent may be contained in at least one of the first amplifying liquid and the second amplifying liquid.
  • the amplifying liquid when the amplifying liquid is of the two-liquid type, the first amplifying liquid permeates the test strip and is developed toward the test area by the capillary force of the test strip, and the second amplifying liquid , may be applied to the surface of the test strip and at least a portion of the second amplification fluid may be spread along the surface toward the test area.
  • the test cartridge of the present disclosure includes a case that houses the test strip and the container, the case having an inner surface that faces the surface of the test strip, and at least part of the amplification liquid is the test strip.
  • the gap between the surface of the case and the inner surface of the case may be used as a flow path to develop toward the inspection area.
  • the antifoaming agent may be applied to the inner surface of the case.
  • the antifoaming agent is added to at least one of the test strip from the sample spotting area to the test area and from the amplification liquid supply position to the test area. may be provided.
  • the antifoaming agent preferably contains at least one of silicone, urethane, acrylic, higher alcohol, higher alcohol derivative, and fatty acid derivative.
  • the test cartridge of the present disclosure includes an absorber that absorbs at least a portion of the amplification liquid that is supplied from the container, flows on the surface of the test strip toward the test area, and has passed through the test area.
  • the absorber when the absorber is provided, the absorber is arranged downstream of the test area in the flow direction of the amplification liquid, and the absorber and the test area do not overlap in the flow direction. is preferred.
  • the absorber when the absorber is provided, it is preferable that the absorber is spaced apart from the test strip.
  • test cartridge of the present disclosure it is possible to improve the throughput of the test by shortening the time until the bubbles generated in the amplification liquid disappear when the test strip is supplied, compared to the conventional art. can.
  • FIG. 1 is a perspective view of a testing cartridge according to the present disclosure
  • FIG. 1 is an exploded perspective view of a testing cartridge according to the present disclosure
  • FIG. 3A is a partially broken side view showing a state in which the first amplification liquid is developed in the test cartridge according to the present disclosure
  • FIG. 3B is a partially broken side view showing a state in which the second amplification liquid is developed.
  • FIG. 4 is a side view showing the positional relationship of a test strip, a multifunctional member, a first amplification liquid holding portion, and a second amplification liquid holding portion in a testing cartridge according to the present disclosure; It is explanatory drawing of the immunochromatography method.
  • FIG. 1 is a perspective view of a testing cartridge according to the present disclosure
  • FIG. 1 is an exploded perspective view of a testing cartridge according to the present disclosure
  • FIG. 3A is a partially broken side view showing a state in which the first amplification liquid is developed in the test cartridge according to the present disclosure
  • FIG. 6A is a partially broken side view showing a state in which the first amplification liquid is developed in Modification 1 of the inspection cartridge
  • FIG. 6B is a partially broken side view showing a state in which the second amplification liquid is developed
  • 7A is a partially broken side view showing a state in which the first amplification liquid is developed in Modification 2 of the inspection cartridge
  • FIG. 7B is a partially broken side view showing a state in which the second amplification liquid is developed.
  • 3 is a perspective view showing a state in which one surface 36 of a flow path forming portion 35 is provided with an antifoaming agent A
  • FIG. 9A is a partially broken side view showing a state in which the first amplification liquid is developed in Modification 3 of the inspection cartridge
  • FIG. 10 is a plan view showing the positional relationship between the test strip and the absorber in the test cartridge; 11 is a cross-sectional view along line XI-XI of FIG. 10; FIG. 10 is a plan view showing still another example of the positional relationship between the test strip and the absorber in the test cartridge; 13 is a cross-sectional view along line XIII-XIII of FIG. 12; FIG.
  • test cartridge according to an embodiment of the present invention will be described below with reference to the drawings.
  • Components shown using the same reference numerals in each drawing mean the same components. However, unless otherwise specified in the specification, each component is not limited to one, and a plurality of components may exist.
  • the directions indicated by arrows X and Y shown as appropriate in each figure are directions along the horizontal plane and are orthogonal to each other. Also, the direction indicated by the arrow Z is the direction along the vertical direction (vertical direction). It is assumed that the directions indicated by arrows X, Y, and Z in each figure match each other.
  • FIG. 1 is an external view of an inspection cartridge 100 (hereinafter referred to as cartridge 100) of one embodiment
  • FIG. 2 is an exploded perspective view of cartridge 100.
  • FIG. 3 shows a state in which the first amplification solution 41 and the second amplification solution 46 are developed on the test strip 1.
  • FIG. 3A shows the state in which the first amplification liquid 41 is developed
  • FIG. 3B shows the state in which the second amplification liquid 46 is developed.
  • FIG. 4 is a diagram showing main components contained within the cartridge 100.
  • FIG. 5 is explanatory drawing of the immunochromatography method.
  • the cartridge 100 is a single-use type that is used one by one for each sample to be tested. Inside the cartridge 100, as shown in FIG. 2, a test strip 1 containing an immunochromatographic carrier 2 (hereinafter referred to as carrier 2) is provided inside the cartridge 100. A test region L1 is provided on the carrier 2, and the coloring state changes depending on whether the sample contains the test substance, that is, whether the sample is positive or negative. Further, as shown in FIG. 3, the cartridge 100 includes a storage section that stores an amplification liquid that amplifies the color development of the inspection region L1, and an antifoaming agent A that eliminates bubbles B generated in the amplification liquid.
  • carrier 2 immunochromatographic carrier 2
  • the amplification solution includes a first amplification solution 41 and a second amplification solution 46, and by reacting the first amplification solution 41 and the second amplification solution 46 on the test strip 1, the region L1 is amplified.
  • the cartridge 100 includes, as storage portions, the first storage portion 24 that stores the first amplification liquid 41 and the second storage portion 32 that stores the second amplification liquid 46 .
  • the antifoaming agent A is contained in the second amplification liquid 46 .
  • the "change in coloring state” includes a mode in which a first color different from the color of the carrier 2 changes to a second color (that is, discoloration), and a color different from that of the carrier 2. It includes either a mode in which one color changes to another color (ie, coloring) or a mode in which the density of a color changes (ie, density change).
  • the specimen is not particularly limited as long as it may contain the test substance.
  • Specimens are, for example, biological samples, particularly animal (especially human) blood, serum, plasma, cerebrospinal fluid, tears, sweat, urine, pus, nasal discharge, nasal swab, pharyngeal swab, nasal aspirate, or bodily fluids such as sputum, or excrements, organs, tissues, mucous membranes and skins, or swabs containing them, or liquid samples containing animal and plant per se or dried bodies thereof.
  • Antigens, antibodies, proteins, low-molecular-weight compounds, and the like are examples of test substances.
  • the cartridge 100 has a configuration that allows the user to visually confirm whether the sample is positive or negative.
  • a cartridge 100 is also called an immunochromatographic test tool or an immunochromatographic test kit.
  • the cartridge 100 includes, for example, a case 9 composed of a case body 20 and a cover member 10.
  • the case 9 is made of, for example, a resin material.
  • the case main body 20 has an opening formed in the upper part, and accommodates therein the test strip 1 as well as the first amplifying solution holding part 40 and the second amplifying solution holding part 45 .
  • the cover member 10 is attached to the opening of the case body 20 to cover the opening of the case body 20 .
  • the case 9 has an elongated shape as a whole in accordance with the elongated shape of the test strip 1 .
  • a drip port 16 , an observation window 18 , a first pressing operation portion 11 and a second pressing operation portion 12 are provided on the upper portion of the case 9 formed by the cover member 10 in this example. These parts are integrally formed with the cover member 10 as an example.
  • the drip port 16 is an opening for dripping the specimen inside the case 9 .
  • a boss is erected upward on the edge of the drip port 16 .
  • the observation window 18 is an opening for observing the inspection region L1 from the outside. possible size. The user can confirm whether the sample is positive or negative by observing the color development state of the inspection region L1 through the observation window 18 .
  • the first pressing operation portion 11 is an operation portion operated to supply the first amplification liquid 41 in the first amplification liquid holding section 40 to the test strip 1.
  • the second pressing operation part 12 is an operation part operated to supply the second amplification liquid 46 in the second amplification liquid holding part 45 to the test strip 1 .
  • the first amplification liquid 41 and the second amplification liquid 46 are amplification liquids for amplifying the coloring of the test region L1 when the specimen is positive, as will be described later.
  • the first pressing operation portion 11 deforms.
  • the first pressing operation part 11 has a quadrangular pyramid shape. , the vertices of the quadrangular pyramid are deformed so as to sink into the case 9 .
  • the first pressing operation portion 11 of this example is provided with a ridge portion 11b that abuts on the first amplification liquid holding portion 40 .
  • the ridge portion 11 b presses the first amplifying solution holding portion 40 inside the case 9 via the end portion of the test strip 1 . A part of the first amplifying solution holding part 40 is broken by this pressing.
  • test strip 1 enters the first amplifying solution holding part 40 from this broken portion and is immersed in the first amplifying solution 41 .
  • test strip 1 is made of a porous material. Therefore, the first amplification liquid 41 is sucked into the test strip 1 by capillary force from the portion of the test strip 1 immersed in the first amplification liquid 41 . Thereby, the first amplification liquid 41 is supplied to the test strip 1 .
  • the first amplification liquid 41 supplied to the test strip 1 soaks into the test strip 1 and spreads toward the test area L1 by capillary action of the test strip 1 .
  • the second pressing operation portion 12 deforms.
  • the second pressing operation portion 12 of this example also has a quadrangular pyramid shape, similarly to the first pressing operation portion 11, and a pressing force is applied from above to an area including the apex of the quadrangular pyramid. is applied, the apex of the quadrangular pyramid is deformed so as to sink into the interior of the case 9, as shown in FIG. 3B.
  • the second pressing operation portion 12 of this example is provided with a contact portion 12 b that contacts the second amplification liquid holding portion 45 . When the second pressing portion 12 is deformed, the contact portion 12b presses the second amplification liquid holding portion 45 inside the case 9.
  • a portion of the second amplification liquid holding portion 45 is broken by the pressing force applied from the contact portion 12b.
  • the second amplifying solution holding part 45 is arranged at a position facing the surface of the test strip 1 with a gap between it and the surface of the test strip 1 .
  • the second amplification liquid holding portion 45 is broken, the second amplification liquid 46 held by the second amplification liquid holding portion 45 flows out to the surface of the test strip 1 from the broken portion. Thereby, the second amplification liquid 46 is supplied to the test strip 1 .
  • the second amplification liquid 46 supplied to the surface of the test strip 1 is spread along the surface of the test strip 1 toward the test area L1. A part of the second amplifying liquid 46 that has reached the inspection area L1 infiltrates the inspection area L1.
  • the second amplification liquid 46 is supplied to the test strip 1 in the same manner as the first amplification liquid 41, but the second amplification liquid 46 is the first amplification liquid that develops in the test strip 1 by capillary force. Unlike the amplification liquid 41 , it flows over the surface of the test strip 1 .
  • the antifoaming agent A contained in the second amplification liquid 46 is supplied to the test strip 1 together with the second amplification liquid 46 .
  • bubbles B may be generated in the second amplification liquid 46 in the configuration of the present embodiment.
  • the antifoaming agent A has a function of eliminating the bubbles B generated in the second amplification liquid 46 .
  • the antifoaming agent A is contained in the second amplification liquid 46 in this embodiment.
  • Defoamer A includes, for example, one of silicones, urethanes, acrylics, higher alcohols, higher alcohol derivatives and fatty acid derivatives. By containing these, the foam B can be efficiently eliminated.
  • antifoaming agents include KS series such as KF-6701 and KS-530 manufactured by Shin-Etsu Chemical Co., Ltd., KM series such as KM-73, Bismer FS series and Bismer CS series manufactured by Nisshin Chemical Laboratory Co., Ltd., and many others.
  • ST series such as Mokukagaku's ST-14, SN series such as SN-1, SN series such as SA-100 and SN-100, Aqualen series such as Kyoeisha Kagaku's Aqualen 8020, BYK-Chemie's BYK-024 There are BYK series such as.
  • the case body 20 accommodates the test strip 1 including the carrier 2 along the longitudinal direction.
  • the case main body 20 has a first amplifying solution holding portion 40 arranged at one longitudinal end (the right end in FIG. 4).
  • a recessed first accommodating section 24 is formed in conformity with the shape of the first amplification liquid holding section 40 .
  • One end of the test strip 1 is placed above the first amplifying solution holding portion 40 that is housed in the first housing portion 24 .
  • the first amplification solution holding section 40 holds the first amplification solution 41.
  • the first amplifying liquid holding part 40 is made of, for example, a resin material and is composed of a container 42 having an opening on one side and a breakable sheet member 43 that covers the opening of the container 42 .
  • the container 42 is filled with the first amplification liquid 41 and the opening of the container 42 is sealed with a sheet member 43 .
  • the first amplifying solution holding section 40 is arranged in the first housing section 24 with the sheet member 43 facing upward.
  • the ridge portion 11b presses the first amplifying solution holding portion 40 via the end portion of the test strip 1 .
  • the ridge portion 11b presses the sheet member 43 of the first amplifying liquid holding portion 40, and the sheet member 43 is thereby broken.
  • the end of the test strip 1 (more specifically, the liquid transfer pad 4 described later) is immersed in the first amplification liquid 41 .
  • the cartridge 100 includes a multifunctional member 30 having a function of accommodating the second amplifying liquid holding portion 45.
  • the multifunctional member 30 is arranged on the other end of the case body 20 (the end on the left side of the paper surface of FIG. 4) and above the test strip 1 .
  • the multifunctional member 30 is a member in which a second housing portion 32 and a flow path forming portion 35 are integrally formed.
  • the multifunctional member 30 is a member having a second accommodating portion 32 and a function of blocking the test strip 1 from the outside, and constitutes a member of the case 9 together with the case main body 20 and the cover member 10 .
  • the second housing portion 32 is a portion that houses the second amplification liquid holding portion 45 .
  • the second housing portion 32 has a box shape with an open top. As shown in FIG. 4, at the bottom of the second housing portion 32, there are projections 34 for breaking a later-described sheet member 48 of the second amplification liquid holding portion 45, and a projection portion 34 for breaking the sheet member 48, which will be described later, of the second amplification liquid holding portion 45.
  • a supply port 32A for supplying the second amplification liquid 46 toward the carrier 2 is provided.
  • the flow path forming portion 35 is provided so as to be connected to the second housing portion 32 .
  • the flow path forming part 35 has a flat plate shape, is arranged at a position facing the inspection area L1 and the like in the longitudinal direction of the inspection strip 1, and is spaced apart from the inspection strip 1. placed.
  • the flow path forming portion 35 has a second amplifying portion flowing out from the second containing portion 32 between the surface of the test strip 1 and one surface 36 of the flow path forming portion 35 facing the surface of the test strip 1 .
  • a channel is formed to flow the liquid 46 toward the inspection region L1 or the like.
  • the flow path forming portion 35 is a member of the case 9 and its one surface 36 corresponds to part of the inner surface of the case 9 .
  • the case 9 has an inner surface (here, one surface 36) facing the surface of the test strip 1, and at least part of the second amplification liquid 46 is between the surface of the test strip 1 and the inner surface of the case.
  • the gap C is used as a flow path and developed toward the inspection area L1.
  • the flow path forming portion 35 is arranged between the observation window 18 and the inspection area L1 of the inspection strip 1 and the like.
  • the flow path forming portion 35 is made of a transparent member, and the inspection area L1 and the like can be observed through the observation window 18 .
  • the second amplification liquid holding section 45 holds the second amplification liquid 46 .
  • the antifoaming agent A is contained in the second amplification liquid 46 , so the second amplification liquid holding section 45 holds the antifoaming agent A together with the second amplification liquid 46 .
  • the second amplifying liquid holding part 45 is made of, for example, a resin material and is composed of a container 47 having an opening on one side and a breakable sheet member 48 that covers the opening of the container 47 .
  • a container 47 is filled with the second amplification liquid 46 and the opening of the container 47 is sealed with a sheet member 48 .
  • the second amplifying solution holding portion 45 is arranged in the second containing portion 32 with the sheet member 48 facing downward. As a result, the sheet member 48 faces the projecting portion 34 inside the second accommodating portion 32 .
  • the second amplifying liquid holding part 45 is pressed downward, whereby the sheet member 48 is pressed against the projecting part 34 .
  • the sheet member 48 is broken.
  • the second amplification liquid 46 flows out through the channel formed by the supply port 32 ⁇ /b>A at the bottom of the second containing portion 32 and the channel forming portion 35 .
  • the second amplification liquid 46 flows out from the supply port 32A at the bottom of the second containing section 32 toward the carrier 2, and the second amplification liquid 46 that has flowed out flows through the flow path formed by the gap C to cover at least the examination area. It reaches up to L1. A portion of the second amplification liquid 46 that has reached the inspection region L1 infiltrates into the carrier 2 from the channel, and a portion passes through the inspection region L1.
  • the case main body 20 is formed with a support portion 22 that supports the end portion of the test strip 1 including the absorbent pad 6 at a position facing the absorbent pad 6 .
  • a second receiving portion 32 of the multifunctional member 30 is arranged above the absorbent pad 6 .
  • the support portion 22 also supports the multifunctional member 30 via the absorbent pad 6 .
  • the case main body 20 is formed with a supporting portion 21 for supporting the central portion of the test strip 1 .
  • a test strip 1 comprises a carrier 2 , a liquid transfer pad 4 and an absorbent pad 6 .
  • the carrier 2 is fixed and supported on the back pressure-sensitive adhesive sheet 7 .
  • the carrier 2 is a porous insoluble carrier for developing the specimen 50, and has an inspection area L1, a control area L2 and a coloring area L3.
  • the carrier 2 also comprises an indicator-retaining pad 3 .
  • the label holding pad 3 constitutes a spotting area onto which the sample 50 is spotted from the dropping port 16 .
  • the coloring area L3 is arranged downstream of the inspection area L1.
  • the inspection area L1, the control area L2, and the coloring area L3 are line-shaped areas extending in a direction perpendicular to the developing direction of the specimen 50 on the carrier 2, respectively.
  • test area L1 the control area L2, and the coloring area L3 are shown as lines, they are not always expressed. Although the details will be described later, before developing the specimen 50 (see FIG. 5), the first amplification solution 41 (see FIG. 4) and the second amplification solution 46 (see FIG. 4), the inspection region L1 and the control region L2 Since the color is substantially the same as the color of the carrier 2 (for example, white), it is not possible to clearly see the inspection area L1 and the control area L2 at this stage.
  • the test area L1 is developed as a line by developing the specimen 50 and increasing the color development density when the developed specimen 50 is positive. Since the color development of the inspection area L1 is amplified by silver amplification, which will be described later, the inspection area L1 develops a black color.
  • the control area L2 also appears as a line due to the increase in color development density when the specimen 50 is developed. As a result, the control area L2 becomes visible. Since the coloring of the control region L2 is also silver-amplified, the control region L2 also develops a black color.
  • the coloring region L3 appears as a dark green line with a black tint (hereinafter referred to as dark green) even before the first amplification solution 41 is developed, and is visible.
  • dark green a black tint
  • the coloring region L3 appears as an orange line by changing the color from dark green to orange.
  • the carrier 2 for example, a porous material such as a nitrocellulose membrane can be used.
  • the back adhesive sheet 7 to which the carrier 2 is fixed is a sheet-like base material having an adhesive surface on which the carrier 2 is attached.
  • a labeling substance 53 is immobilized on the label holding pad 3 .
  • the labeling substance 53 is modified with a first binding substance 52 that specifically binds to the test substance 51 contained in the specimen 50 .
  • the label holding pad 3 is fixed on the carrier 2 at a position facing the drip port 16 (see FIG. 2) of the cover member 10 . Accordingly, the sample 50 is dropped onto the label holding pad 3 from the dropping port 16 . Therefore, the label holding pad 3 corresponds to a spotting area on which the sample 50 is spotted.
  • the label holding pad 3 is fixed at approximately the central position of the carrier 2 in the longitudinal direction.
  • the labeling substance 53 for example, colloidal gold particles (EM.GC50, manufactured by BBI) having a diameter of 50 nm can be used.
  • the labeling substance 53 is not limited to colloidal gold, and metal sulfides that can be used in normal chromatography, colored particles that are used in immunoagglutination, and the like can be used, and colloidal metals are particularly preferred.
  • metal colloids include colloidal gold, colloidal silver, colloidal platinum, colloidal iron, colloidal aluminum hydroxide, and composite colloids thereof. gold colloid is most preferable among them.
  • the inspection region L1 contains a second binding substance 56 that specifically binds to the test substance 51 and captures the test substance 51 .
  • the second binding substance 56 binds to the test substance 51 and captures the test substance 51 in the inspection region L1
  • the first binding substance 52 and the labeling substance 53 bound to the test substance 51 are captured. be.
  • the specimen 50 contains the test substance 51
  • the test substance 51 and the labeling substance 53 are captured in the test region L1, so that the color density of the test region L1 rises above a preset standard.
  • the inspection area L ⁇ b>1 is an area for confirming the presence or absence of the test substance 51 based on the labeling signal from the labeling substance 53 captured through the test substance 51 .
  • the control region L2 contains a third binding substance 58 that specifically binds to the first binding substance 52 and captures the labeling substance 53 via the first binding substance 52 .
  • the labeling substance 53 that is not bound to the test substance 51 among the labeling substances 53 modified with the first binding substance 52 is also included in the test region L1 together with the sample 50.
  • the inside of the carrier 2 is developed toward the .
  • the labeling substance 53 that is not bound to the test substance 51 passes through the inspection area L1 without being captured by the inspection area L1.
  • the labeling substance 53 that has passed through the inspection region L1 is captured in the control region L2 via the first binding substance 52 as the first binding substance 52 binds to the third binding substance 58 .
  • the control area L2 is an area for confirming the completion of the development of the specimen 50 based on the labeling signal from the labeling substance 53 captured via the first binding substance 52 . Therefore, the control area L2 is sometimes called a confirmation area.
  • the coloring region L3 contains a substance that reacts with the first amplification liquid 41 to change the coloring state.
  • the coloring region L3 reacts with the first amplification liquid 41 to develop color or change color, thereby indicating that the first amplification liquid 41 has spread to that region.
  • a mixed aqueous solution of iron nitrate aqueous solution and citric acid manufactured by Wako Pure Chemical Industries, Ltd., 038-06925
  • bromocresol green (Wako Pure Chemical Industries, Ltd. ) company
  • the coloring region L3 is preferably formed by a coloring reagent immobilization line.
  • This aspect is the aspect of the coloring region L3 of this example.
  • the coloring region L3 of this example is dark green before reacting with the first amplification liquid 41, and the first amplification liquid 41 When it reaches L3, it changes to orange.
  • the coloring region L3 is also called an amplification indicator region because it indicates the timing of the development of the first amplification liquid 41 and the supply of the second amplification liquid 46 by changing the coloring state.
  • the first binding substance 52 that modifies the labeling substance 53 and specifically binds to the test substance 51 is, for example, an antibody against the antigen if the test substance is an antigen, or an antibody that is the test substance.
  • the test substance is a protein or a low-molecular-weight compound, it is a substance that specifically binds to the test substance, such as an aptamer for the protein or the low-molecular-weight compound.
  • the second binding substance 56 fixed to the test region L1 and specifically binding to the test substance 51 is, for example, an antibody against the antigen when the test substance is an antigen, or an antibody against the test substance.
  • the test substance is a protein or a low-molecular-weight compound, it is a substance that specifically binds to the test substance, such as an aptamer for the protein or the low-molecular-weight compound.
  • the first binding substance 52 and the second binding substance 56 may be the same or different.
  • the third binding substance 58 that specifically binds to the first binding substance 52 may be the test substance 51 itself or a compound having a site recognized by the first binding substance 52.
  • a compound obtained by binding a derivative of the substance 51 to a protein may be used.
  • the first binding substance 52 and the second binding substance 56 are anti-influenza A monoclonal antibody (Anti-Influenza A SPTN-5 7307, Medix Biochemical company), and an anti-mouse IgG antibody (anti-mouse IgG (H+L), rabbit F(ab′)2, product number 566-70621, manufactured by Wako Pure Chemical Industries, Ltd.) is used as the third binding substance 58.
  • Anti-Influenza A SPTN-5 7307 Medix Biochemical company
  • an anti-mouse IgG antibody anti-mouse IgG (H+L), rabbit F(ab′)2, product number 566-70621, manufactured by Wako Pure Chemical Industries, Ltd.
  • the liquid-feeding pad 4 is arranged in contact with one end of the carrier 2, and upstream of the spotting area in the flow direction of the specimen from the spotting area formed by the label holding pad 3 toward the inspection area L1.
  • the first amplification liquid 41 is sent to the carrier 2 from the side.
  • One end of the liquid-feeding pad 4 is immersed in the first amplification liquid holding section 40 when the first pressing operation portion 11 is pressed.
  • the liquid-feeding pad 4 is made of a porous material, absorbs the first amplification liquid 41, and feeds the absorbed first amplification liquid 41 to the carrier 2 by capillary action.
  • the absorbent pad 6 is arranged in contact with the other end of the carrier 2 and absorbs at least the specimen 50 and the first amplification liquid 41 developed on the carrier 2 . As shown in FIG. 4 , the absorbent pad 6 is arranged upstream of the supply point of the second amplification liquid 46 in the flow direction of the second amplification liquid 46 .
  • the flow direction of the second amplification liquid 46 is the direction from the supply point of the second amplification liquid 46 toward the inspection area L1, and the sample 50 spotted on the label holding pad 3 flows toward the inspection area L1. The direction is the opposite direction.
  • the absorbent pad 6 develops in a direction opposite to the flow direction of the second amplification liquid 46 and absorbs the sample 50 that has passed through the inspection region L1. Also, the absorbent pad 6 absorbs the first amplification liquid 41 that is sent to the carrier 2 via the liquid-sending pad 4 .
  • the absorbent pad 6 is made of a porous material and absorbs the sample 50 and the first amplification liquid 41 from inside the carrier 2 by capillary force. Since the absorbent pad 6 sequentially absorbs the specimen 50 and the first amplification solution 41 at the end of the carrier 2, the specimen 50 and the first amplification solution 41 are suppressed from staying in the carrier 2, and the specimen 50 and the first amplification solution 41 are suppressed.
  • the amplifying liquid 41 can be smoothly flowed toward the absorbent pad 6. - ⁇ As a result, the specimen 50 and the first amplification liquid 41 can be smoothly flowed from the label holding pad 3, which is the spotting area of the specimen 50, toward the inspection area L1.
  • the amplification solution for amplifying the color development of the test area L1 includes the first amplification solution 41 and the second amplification solution 46, and the first amplification solution 41 and the second amplification solution are mixed on the test strip 1. It is a two-liquid type that amplifies the color development of the inspection region L1 and the control region L2 by reacting with the two-amplification liquid 46 .
  • a metallic labeling substance such as colloidal gold
  • silver amplification is used as a method for amplifying the labeling signal of the labeling substance 53, for example.
  • the first amplification liquid 41 and the second amplification liquid 46 are amplification liquids used for silver amplification, for example, and the reaction of the first amplification liquid 41 and the second amplification liquid 46 with the labeling substance 53 as a catalyst is the amplification reaction. .
  • the amplification reaction produces silver particles having a particle diameter relatively larger than that of the labeling substance 53 .
  • the first amplification liquid 41 is a reducing agent that reduces silver ions
  • the second amplification liquid 46 is silver ions.
  • any inorganic or organic material or a mixture thereof can be used as the reducing agent for the first amplification liquid 41 as long as it can reduce the silver ions used for the second amplification liquid 46 to silver.
  • Preferred examples of the inorganic reducing agent include reducing metal salts and reducing metal complexes whose valence can be changed with metal ions such as Fe 2+ , V 2+ and Ti 3+ . When using inorganic reducing agents, it is necessary to complex or reduce the oxidized ions to remove or render them harmless.
  • citric acid or EDTA ethylenediaminetetraacetic acid
  • EDTA ethylenediaminetetraacetic acid
  • Developing agents used in wet silver halide photographic light-sensitive materials for example, methyl gallate, hydroquinone, substituted hydroquinone, 3-pyrazolidones, p-aminophenols, p-phenylenediamines, hindered phenols, amidoxime azines, azines, catechols, pyrogallols, ascorbic acid (or its derivatives), and leuco dyes), and other materials apparent to those skilled in the art, such as those described in U.S. Pat. No. 6,020,117. can also be used.
  • an ascorbic acid reducing agent is also preferable.
  • useful ascorbic acid reducing agents include ascorbic acid and analogues, isomers and derivatives thereof, such as D- or L-ascorbic acid and its sugar derivatives such as ⁇ -lactoascorbic acid, glucoascorbic acid, fucoascorbic acid , glucoheptoacorbic acid, maltoascorbic acid), sodium salt of ascorbic acid, potassium salt of ascorbic acid, isoascorbic acid (or L-erythroascorbic acid), salts thereof (eg alkali metal salts, ammonium salts or the art known salt), enediol-type ascorbic acid, enaminol-type ascorbic acid, thioenol-type ascorbic acid, etc., particularly D, L or D, L-ascorbic acid (and , its alkali metal salt) or isoascorbic acid (or its alkali metal salt
  • a solution in which a compound containing silver ions is dissolved in a solvent is preferable.
  • Organic silver salts, inorganic silver salts, or silver complexes can be used as silver ion-containing compounds. Inorganic silver salts or silver complexes are preferred.
  • the inorganic silver salt it is possible to use a silver ion-containing compound that is highly soluble in a solvent such as water, such as silver nitrate, silver acetate, silver lactate, silver butyrate, and silver thiosulfate. Silver nitrate is particularly preferred.
  • a silver complex coordinated with a ligand having a water-soluble group such as a hydroxyl group or a sulfone group is preferable, and examples thereof include hydroxythioether silver.
  • the sample 50 is spotted on the marker holding pad 3, which is the spotting area (step S1).
  • a test substance 51 in a specimen 50 spotted on the label-holding pad 3 specifically binds to a first binding substance 52 that modifies the labeling substance 53 contained in the label-holding pad 3 .
  • the specimen 50 is developed in the carrier 2 from the label holding pad 3 toward the inspection area L1 by capillary action in the carrier 2 . Note that part of the specimen 50 is also developed in the direction opposite to the inspection area L1.
  • the first amplification liquid 41 is supplied (step S2).
  • the first amplification liquid 41 is supplied from the liquid-sending pad 4 side.
  • the first amplification liquid 41 is supplied to the carrier 2 via the liquid-sending pad 4 and spreads toward the inspection area L1.
  • step S3-S4 wait until the first amplification solution 41 is developed in the inspection area L1 (steps S3-S4).
  • "Wait" shown in FIG. 5 means waiting.
  • the first amplification liquid 41 is gradually developed toward the inspection area L1, and the specimen 50 being developed from the label holding pad 3 and the labeling substance 53 modified with the first binding substance 52 are pushed by the first amplification liquid 41. As shown, it is developed toward the inspection area L1 (step S3).
  • the test substance 51 in the specimen 50 that has reached the inspection region L1 is captured by the second binding substance 56 in the inspection region L1. That is, the labeling substance 53 bound to the test substance 51 via the first binding substance 52 is captured in the inspection region L1. On the other hand, the labeling substance 53 not bound to the test substance 51 passes through the inspection region L1 without being captured and is captured by the third binding substance 58 in the control region L2.
  • the coloring region L3 reacts with the first amplification liquid 41 to change the coloring state.
  • the coloring region L3 is dark green before reacting with the first amplification liquid 41, and changes color to orange after reacting with the first amplification liquid 41.
  • the second amplification liquid 46 is supplied to the carrier 2 (step S5).
  • the second amplifying liquid 46 is supplied to the carrier 2 from the absorbent pad 6 side of the coloring area L3 and spreads toward the inspection area L1.
  • the first amplification liquid 41 is a first amplification liquid containing a reducing agent that reduces silver ions
  • the second amplification liquid 46 is a second amplification liquid containing silver ions.
  • Silver particles 60 are generated by the reaction of the first amplification liquid and the second amplification liquid with the colloidal gold particles as the labeling substance 53 as a catalyst. This amplifies the label signal (step S6).
  • the antifoaming agent A contained in the second amplification liquid 46 is developed together with the second amplification liquid 46 toward the inspection area L1. , the bubbles B generated in the second amplification liquid 46 disappear.
  • the first amplification liquid 41 is developed toward the inspection area L1 by capillary action in the liquid-feeding pad 4 and the carrier 2 .
  • the second amplification liquid 46 flows on the surface of the test strip 1 using the gap C between the flow path forming portion 35 of the multifunctional member 30 and the surface of the carrier 2 as a flow path, and is developed in the test area L1.
  • Bubbles B may be generated in the gap C.
  • bubbles B may be generated in the inspection region L1 arranged at a position facing the flow path forming portion 35 of the carrier 2 and its surroundings. . It is speculated that one of the causes of the generation of the bubbles B is that the second amplification liquid 46 flows vigorously into the gap C, and the remaining air and the second amplification liquid 46 are mixed. It is also presumed that the air in the carrier 2 rises to the surface of the carrier 2 when the second amplification liquid 46 that has flowed into the gap C infiltrates into the carrier 2 . It is presumed that at least one of these causes the generation of bubbles B.
  • the bubbles B generated in the second amplification liquid 46 become noise when determining the coloring state of the inspection region L1. Therefore, it is necessary to wait until the bubble B disappears in order to make an accurate judgment in the inspection.
  • the cartridge 100 of the present disclosure includes the antifoaming agent A that eliminates the bubbles B generated in the amplification liquid (the second amplification liquid 46 in this example), so that the second amplification liquid 46
  • the bubble B can be eliminated without waiting until it retreats from the inspection area L1. Therefore, compared with the conventional cartridge which does not have the antifoaming agent A, the foam B can be quickly eliminated. Since the time until the bubbles B generated in the inspection area L1 disappear can be shortened, the inspection throughput can be improved.
  • Disappearance of the bubble B means that at least part of the bubble B generated in the amplification liquid disappears.
  • the "time until disappearance” refers to the time required for all the bubbles B in the amplification liquid to disappear, as well as the disappearance of some of the bubbles B, which causes noise in the signal representing the state of color development in the inspection area. It means the time until the amount of the bubble B that is formed is reduced to a range that does not affect the inspection accuracy.
  • the antifoaming agent A is contained in the second amplification liquid 46, and is developed together with the second amplification liquid 46 toward the inspection area L1 (see enlarged view in FIG. 3B). . Therefore, the effect of causing the bubble B to disappear before the second amplification liquid 46 reaches the inspection area L1 can be expected. As a result, the bubbles B in the second amplification liquid 46 developed in the inspection area L1 can be eliminated relatively early.
  • the two-liquid type amplification liquid containing the first amplification liquid 41 and the second amplification liquid 46 amplifies the coloring of the inspection region L1.
  • a form in which the coloring of the inspection region L1 is amplified with a single amplification solution may be used.
  • a single storage section containing a single amplification liquid is provided instead of the first storage section and the second storage section. good.
  • the antifoaming agent A is contained in the second amplification liquid 46.
  • the cartridge 100 may be provided elsewhere in the
  • the antifoaming agent A may be contained in the first amplification liquid 41, or may be the inner surface of the case 9 that the first amplification liquid 41 or the second amplification liquid 46 touches in the case 9, or the first amplification liquid 41.
  • it may be provided in the carrier 2 through which the second amplification liquid 46 passes. Modifications will be described below with reference to FIGS. 6 to 9. FIG.
  • FIG. 6 shows a form in which the antifoaming agent A is contained in the first amplification liquid 41.
  • FIG. 6A is a diagram showing a state in which the antifoaming agent A is contained in the first amplifying liquid holding portion 40
  • FIG. 6B shows a state in which the second amplifying liquid 46 is supplied to the test strip 1.
  • FIG. It is a diagram.
  • the antifoaming agent A is contained in the first amplification liquid 41.
  • the end of the test strip 1 is immersed in the first amplification liquid 41 by pressing the first pressing operation part 11 .
  • the antifoaming agent A is also sucked up by the test strip 1 .
  • the antifoaming agent A is spread inside the test strip 1 toward the test area L1 by capillary action together with the first amplification liquid 41 .
  • FIG. 6B at least a portion of the antifoaming agent A is transported to the region of the test strip 1 from the supply position of the second amplification liquid 46 to the test region L1.
  • the second amplification liquid 46 is supplied to the test strip 1 while the antifoaming agent A is spread over the area from the inspection area L1 to the supply position of the second amplification liquid 46 (see FIG. 6B). ). While entraining the bubbles B generated when the second amplification liquid 46 is supplied to the test strip 1, the second amplification liquid 46 fills the gap between the surface of the test strip 1 and the one surface 36 of the flow path forming portion 35. C is flowed toward the inspection area L1. A second amplification liquid 46 containing foam B passes through the region where antifoam A is deployed (see enlarged view in FIG. 6B).
  • the second amplifying liquid 46 comes into contact with the antifoaming agent A existing in the region from the supply position to the inspection region L1, and the antifoaming agent A is mixed in the second amplifying liquid 46 (enlarged view in FIG. 9B). (see diagram).
  • the antifoaming agent A is mixed in the second amplification liquid 46, the bubbles B generated in the second amplification liquid 46 disappear due to the action of the antifoaming agent A.
  • the antifoaming agent A is contained in at least one of the first amplification liquid 41 and the second amplification liquid 46, similar effects can be obtained.
  • the antifoaming agent A may be contained in both the first amplification liquid 41 and the second amplification liquid 46 . If both the first amplifying solution 41 and the second amplifying solution 46 contain the antifoaming agent A, the bubbles B will form earlier than the case where only one of them contains the antifoaming agent A. can be expected to eliminate
  • FIG. 7 is a diagram showing a form in which the antifoaming agent A is applied to the inner surface of the case 9.
  • FIG. 7A is a diagram showing a state in which the antifoaming agent A is provided on one surface 36 of the flow path forming portion 35, which is the inner surface of the case 9, and FIG. It is a figure which shows the state supplied.
  • FIG. 8 is a perspective view showing a state in which the antifoaming agent A is provided on one surface 36 of the flow path forming portion 35 of the multifunctional member 30. As shown in FIG.
  • the antifoaming agent A is provided in a region facing the carrier 2 near the center in the width direction of the one surface 36 of the flow path forming portion 35 .
  • the second amplification liquid 46 is supplied to the test strip 1, and the space between the surface of the test strip 1 and the inner surface of the case 9 (here, one surface 36 of the flow path forming portion 35) Using the gap C as a flow path, it is developed toward the inspection area L1. At this time, bubbles B are generated in the second amplification liquid 46 as shown in the enlarged view of FIG. 7B.
  • the second amplification liquid 46 contacts the one surface 36 and spreads toward the inspection area L1 while taking in the antifoaming agent A. As shown in FIG.
  • the antifoaming agent A is provided on the inner surface of the case 9 that contacts when the second amplification liquid 46 is developed toward the inspection area L1.
  • the antifoaming agent A is mixed in the second amplification liquid 46.
  • the effect of causing the bubble B to disappear before the amplification liquid 46 reaches the inspection area L1 can be expected.
  • the bubbles B in the second amplification liquid 46 developed in the inspection area L1 can be eliminated relatively early.
  • FIG. 9 shows a form in which the antifoaming agent A is provided on the test strip 1 .
  • 9A is a diagram showing a state in which the antifoaming agent A is provided in the test strip 1 between the label holding pad 3, which is the spotting area of the sample 50, and the test area L1, and
  • FIG. 3 shows a state in which a second amplifying liquid 46 is supplied to the test strip 1.
  • the antifoaming agent A is provided in the area between the label holding pad 3 and the inspection area L1 of the test strip 1 (here, the carrier 2).
  • the antifoaming agent A inspects the inside of the test strip 1 together with the sample 50 or the first amplification solution 41 when the sample 50 or the first amplification solution 41 develops in the test strip 1 toward the inspection region L1. Deployed toward the area L1. As shown in FIG. 9B, at least a portion of the antifoaming agent A is transported to the region of the test strip 1 from the supply position of the second amplification liquid 46 to the test region L1.
  • the second amplification liquid 46 is supplied to the test strip 1 while the antifoaming agent A is spread over the area from the inspection area L1 to the supply position of the second amplification liquid 46 (see FIG. 9B). ). While entraining the bubbles B generated when the second amplification liquid 46 is supplied to the test strip 1, the second amplification liquid 46 fills the gap between the surface of the test strip 1 and the one surface 36 of the flow path forming portion 35. C is flowed toward the inspection area L1. A second amplification liquid 46 containing foam B passes through the region where antifoam A is developed (see enlarged view in FIG. 9B).
  • the second amplifying liquid 46 comes into contact with the antifoaming agent A existing in the region from the supply position to the inspection region L1, and the antifoaming agent A is mixed in the second amplifying liquid 46 (enlarged view in FIG. 9B). (see diagram).
  • the antifoaming agent A is mixed in the second amplification liquid 46, the bubbles B generated in the second amplification liquid 46 disappear due to the action of the antifoaming agent A.
  • the antifoaming agent A is provided between the spotting area of the sample 50 of the test strip 1 and the test area L1.
  • the antifoaming agent A is provided in at least one of the area between the spotting area of the specimen 50 and the inspection area L1 and the area between the amplification liquid supply position and the inspection area L1 in the test strip 1, good.
  • it is an area through which the first amplification liquid 41 is developed in the inspection area L1, or an area through which the second amplification liquid 46 is developed in the inspection area L1.
  • the antifoaming agent A may be provided on the liquid-feeding pad 4 forming one end of the test strip 1 or on the end of the carrier 2 on the side of the liquid-feeding pad 4 . Also, the antifoaming agent A may be provided in the area through which the second amplifying liquid 46 passes, between the absorbent pad 6 in the carrier 2 constituting the test strip 1 and the test area L1.
  • the antifoaming agent A is provided in at least one of the area between the spotting area of the sample 50 and the inspection area L1 and the area between the supply position of the amplifying liquid and the inspection area L1 in the test strip 1, the sample When the test strip 1 is developed by 50 or the amplification liquid (here, the first amplification liquid 41 or the second amplification liquid 46), the antifoaming agent A is carried by the specimen 50 or the amplification liquid to the test area L1. Since the antifoaming agent A is mixed in the amplifying solution during development, even if the bubbles B are generated in the amplifying solution, the bubbles B can be eliminated.
  • the cartridge 100 is provided with the antifoaming agent A as described above to quickly eliminate the bubbles B generated in the amplification liquid, thereby improving the inspection throughput.
  • Cartridge 100 may be provided with antifoaming agent A and may also be provided with another configuration for more efficiently eliminating bubbles B in the amplification liquid.
  • the cartridge 100 includes an absorber 8 that absorbs at least part of the amplification liquid that is supplied from the container, flows on the surface of the test strip 1 toward the test area L1, and has passed through the test area L1. may be provided.
  • FIG. 10 is a plan view of the cartridge 100A with the cover member 10 removed, and is an enlarged view of a region including the absorbent pad 6 and the label holding pad 3.
  • FIG. 11 is a cross-sectional view taken along the line XI--XI of FIG. 10.
  • cartridge 100A The overall configuration of the cartridge 100A is substantially the same as the cartridge 100 described using FIGS. As shown in FIG. 10, cartridge 100A differs from cartridge 100 in that absorbers 8 are provided on both sides of immunochromatographic carrier 2 in the width direction.
  • the absorbent 8 was supplied from the second container 32, flowed over the surface of the test strip 1 toward the test area L1, and passed through the test area L1. At least part of the second amplification liquid 46, which is one of the amplification liquids, is absorbed.
  • the inspection area L1 is arranged downstream of the supply position of the second amplification liquid 46, and the spotting area is arranged further downstream than the inspection area L1.
  • the absorber 8 is arranged downstream of the inspection region L1 in the flow direction of the second amplification liquid 46 (see FIG. 4).
  • the absorber 8 is arranged so as not to overlap with the inspection region L1 in the flow direction of the second amplification liquid 46 . That is, in the longitudinal direction (the Y direction in the figure) of the test strip 1, the absorber 8 is arranged between the test area L1 and the label holding pad 3 corresponding to the spotting area (see FIGS. 2 and 4). see also).
  • the absorbent bodies 8 are arranged on both sides of the test strip 1 in the width direction, and the absorbent bodies 8 and the test strip 1 are arranged with a gap D1 therebetween.
  • the cartridge 100A contains the antifoaming agent A and can eliminate the bubbles B generated in the second amplification liquid 46 .
  • the cartridge 100A includes an absorber 8 that flows over the surface of the test strip 1 toward the test area L1 and absorbs at least a portion of the second amplification liquid 46 that has passed through the test area L1. Therefore, compared with the cartridge 100 without the absorber 8, the cartridge 100A can quickly withdraw the second amplification liquid 46 from the inspection area L1 due to the absorbing action of the absorber 8.
  • the absorber 8 absorbs at least a portion of the second amplification liquid 46 that has passed through the inspection area L1, so that the back flow of the second amplification liquid 46 flowing back toward the inspection area L1 is reduced. Therefore, the second amplification liquid 46 can be withdrawn from the inspection region L1 more quickly than in the conventional art.
  • the absorber 8 is arranged downstream of the inspection area L1 in the flow direction of the second amplification liquid 46, and the absorber 8 and the inspection area L1 are separated from each other. , do not overlap in the flow direction of the second amplification liquid 46 .
  • the absorber 8 With this arrangement, only the second amplification liquid 46 that has passed through the inspection area L1 can be absorbed by the absorber 8, and the second amplification that exerts a coloring amplification effect on the inspection area L1. Absorption of the liquid 46 by the absorber 8 can be suppressed. That is, it is possible to prevent the color amplification effect of the second amplification liquid 46 from deteriorating with respect to the inspection region L1.
  • the absorber 8 may be arranged so as to overlap with the inspection region L1 in the flow direction of the second amplification liquid 46 . If the amount of the second amplifying liquid 46 flowing into the inspection area L1 is large, it may be possible to secure the effect of amplifying the color development by contacting the second amplifying liquid 46 and the inspection area L1 for a short period of time. In that case, priority may be given to shortening the disappearance time of the bubbles B by absorbing the second amplification liquid 46 on the inspection area L1 in a short time.
  • the absorber 8 and the inspection area L1 "do not overlap in the flow direction" means that the end of the inspection area L1 on the side of the absorber 8 shown in FIG. is greater than 0 (D1>0).
  • the absorbent bodies 8 are arranged on both sides in the width direction of the test strip 1, but it is sufficient if they are arranged on at least one of the two sides. However, if the absorbers 8 are arranged on both sides of the test strip 1 in the width direction, the second amplification liquid 46 can be absorbed more quickly than if they are arranged only on one side. As a result, the effect of shortening the disappearance time of the bubble B is high.
  • the absorber 8 is arranged with a gap D2 between it and the test strip 1.
  • the flow direction of the second amplification liquid 46 is opposite to the flow direction of the specimen 50, and the absorbent body 8 has the label holding pad 3, which is the area where the specimen 50 is spotted, and the inspection area L1. is placed between. Therefore, when the specimen 50 is developed from the label holding pad 3 toward the inspection area L1, if the absorbent 8 is in contact with the test strip 1, part of the specimen 50 is absorbed by the absorbent 8, and the inspection area The amount of specimen 50 developed to L1 may decrease. However, in the cartridge 100A, since the absorber 8 is arranged with the interval D2 between the test strip 1 and the test strip 1, the sample 50 can be developed in the test area L1 without being absorbed by the absorber 8.
  • the second amplification liquid 46 flows through the gap C between the surface of the test strip 1 and the one surface 36 of the flow path forming portion 35 as a flow path.
  • the second amplification liquid 46 sandwiched between the surface of the test strip 1 and the flow path forming portion 35 has a portion that protrudes beyond the width of the test strip 1 in the width direction of the test strip 1 due to surface tension. It flows while holding (see FIG. 11). Therefore, as described above, even if the absorber 8 is arranged between the test strips 1 with the gap D2, it can absorb the second amplification liquid 46 flowing through the gap C.
  • the distance D2 between the absorbent body 8 and the test strip 1 is preferably 0.3 mm or more and 1 mm or less, more preferably 0.4 mm or more and 1 mm or less.
  • the distance D2 is preferably 0.3 mm or more and 1 mm or less, more preferably 0.4 mm or more and 1 mm or less.
  • FIG. 12 is a plan view of the cartridge 100B with the cover member 10 removed, and is an enlarged view of a region including the absorbent pad 6 and the label holding pad 3.
  • FIG. 13 is a cross-sectional view taken along the line XIII--XIII of FIG. 12.
  • the overall configuration of the cartridge 100B is also substantially the same as the cartridge 100 described with reference to FIGS.
  • the cartridge 100B differs from the cartridge 100 in that the absorber 8 is arranged at a position at least partially facing the surface of the test strip 1.
  • the absorber 8 is a concave portion provided in the inner surface of the case 9 (here, one surface 36 of the flow path forming portion 35) facing the test strip 1 forming the flow path through which the second amplification liquid 46 flows. 35a.
  • the absorber 8 is accommodated in the recess 35a so that the surface 36 of the flow path forming portion 35 and the surface of the absorber 8 are flush with each other.
  • the distance D2 between the absorber 8 and the test strip 1 is the distance between the surface of the test strip 1 (surface of the carrier 2) and the surface of the absorber 8 facing the test strip 1 (one surface 36).
  • distance, and the interval D2 is the same as the interval C.
  • the distance D2 is preferably 0.3 mm or more and 1 mm or less, more preferably 0.4 mm or more and 1 mm or less.
  • the surface of the absorber 8 may protrude from the one surface 36 of the flow path forming portion 35 or may be recessed.
  • the absorber 8 is positioned on both sides of the test strip 1 in the width direction.
  • the absorber 8 is provided for absorbing at least a portion of the second amplification liquid 46 that flows toward the test area L1 on the surface of the test strip 1 and has passed through the test area L1, the absorber 8
  • the absorber 8 allows the second amplifying liquid 46 that has passed through the inspection area L1 to be discharged from the passage more quickly than when it is not provided.
  • the time until the bubble B disappears can be further shortened, and the inspection throughput can be improved.
  • test strip 1 test strip 2 immunochromatographic carrier (carrier) 3 label holding pad 4 liquid transfer pad 6 absorption pad (second absorber) 7 back adhesive sheet 8 absorber (first absorber) 9 Case 10 Cover member 11 First pressing operation portion 11b Ridge portion 12 Second pressing operation portion 12b Contact portion 16 Drop opening 18 Observation window 20 Case main body 21 Support portion 22 Support portion 24 First storage portion 30 Multifunctional member 32 Second housing portion 32A Supply port 34 Protrusion 35 Channel forming portion 35a Concave portion 36 One surface 40 of channel forming portion First amplification liquid holding portion 41 First amplification liquid 42 Container 43 Sheet member 45 Second amplification liquid holding portion 46 2 amplification liquid 47 container 48 sheet member 50 sample 51 test substance 52 first binding substance 53 labeling substance 56 second binding substance 58 third binding substance 60 silver particles 100, 100A, 100B cartridge (testing cartridge) A antifoaming agent B foam L1 inspection area L2 control area L3 coloring area

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PCT/JP2022/026937 2021-07-30 2022-07-07 検査用カートリッジ Ceased WO2023008129A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP22849194.0A EP4379380A4 (en) 2021-07-30 2022-07-07 INSPECTION CARTRIDGE
JP2023538386A JPWO2023008129A1 (https=) 2021-07-30 2022-07-07

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021126035 2021-07-30
JP2021-126035 2021-07-30

Publications (1)

Publication Number Publication Date
WO2023008129A1 true WO2023008129A1 (ja) 2023-02-02

Family

ID=85086729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/026937 Ceased WO2023008129A1 (ja) 2021-07-30 2022-07-07 検査用カートリッジ

Country Status (3)

Country Link
EP (1) EP4379380A4 (https=)
JP (1) JPWO2023008129A1 (https=)
WO (1) WO2023008129A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025164600A1 (ja) * 2024-01-30 2025-08-07 東ソー株式会社 免疫反応試薬、その製造方法及び免疫反応試薬キット

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020117A (en) 1998-09-30 2000-02-01 Eastman Kodak Company Thermally processable imaging element
JP2002196001A (ja) * 2000-09-22 2002-07-10 Shino Test Corp 被検物質の測定器具及び測定方法
JP2003507741A (ja) * 1999-08-23 2003-02-25 ヴェンディア テック コーポレーション リミテッド 血液サンプルの脱色方法、それを用いた診断方法及び診断キット
JP2010071827A (ja) 2008-09-19 2010-04-02 Fujifilm Corp アッセイ方法
JP2011047788A (ja) * 2009-08-27 2011-03-10 Sysmex Corp 免疫測定用粒子懸濁液及び免疫測定用試薬キット
JP2011099724A (ja) 2009-11-05 2011-05-19 Fujifilm Corp アッセイ用デバイス
JP2016011943A (ja) * 2013-12-24 2016-01-21 株式会社リコー 分析デバイス
WO2018043688A1 (ja) * 2016-08-31 2018-03-08 積水化学工業株式会社 アナライト濃度測定法、凝集蛍光材料含有粒子及び検査デバイス
US20200124593A1 (en) * 2016-06-23 2020-04-23 Memed Diagnostics Ltd. Measuring trail by lateral flow immunoassay

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4094647A (en) * 1976-07-02 1978-06-13 Thyroid Diagnostics, Inc. Test device
FI3489685T3 (fi) * 2011-11-21 2023-12-21 Zoetis Services Llc Signaalin vahvistaminen lateraalivirtaus- ja vastaavissa immunomäärityksissä

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020117A (en) 1998-09-30 2000-02-01 Eastman Kodak Company Thermally processable imaging element
JP2003507741A (ja) * 1999-08-23 2003-02-25 ヴェンディア テック コーポレーション リミテッド 血液サンプルの脱色方法、それを用いた診断方法及び診断キット
JP2002196001A (ja) * 2000-09-22 2002-07-10 Shino Test Corp 被検物質の測定器具及び測定方法
JP2010071827A (ja) 2008-09-19 2010-04-02 Fujifilm Corp アッセイ方法
JP2011047788A (ja) * 2009-08-27 2011-03-10 Sysmex Corp 免疫測定用粒子懸濁液及び免疫測定用試薬キット
JP2011099724A (ja) 2009-11-05 2011-05-19 Fujifilm Corp アッセイ用デバイス
JP2016011943A (ja) * 2013-12-24 2016-01-21 株式会社リコー 分析デバイス
US20200124593A1 (en) * 2016-06-23 2020-04-23 Memed Diagnostics Ltd. Measuring trail by lateral flow immunoassay
WO2018043688A1 (ja) * 2016-08-31 2018-03-08 積水化学工業株式会社 アナライト濃度測定法、凝集蛍光材料含有粒子及び検査デバイス

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025164600A1 (ja) * 2024-01-30 2025-08-07 東ソー株式会社 免疫反応試薬、その製造方法及び免疫反応試薬キット

Also Published As

Publication number Publication date
EP4379380A4 (en) 2024-12-25
JPWO2023008129A1 (https=) 2023-02-02
EP4379380A1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
JP2702498B2 (ja) 免疫検定装置、方法、およびキット
JP6386095B2 (ja) イムノクロマトグラフキット
JP5276568B2 (ja) アッセイ用デバイス
US8303910B2 (en) Biosensor
CN102378913B (zh) 用于分析的方法和装置
JP2007530946A (ja) ハイブリッド相ラテラルフロー・アッセイ
JP7141458B2 (ja) クロマトグラフキットおよびクロマトグラフ方法
JP7554275B2 (ja) 検体液の濃縮方法、及び、検体液の検査方法
JP7425883B2 (ja) 濃縮デバイス、検体液の濃縮方法、検体液の検査方法、及び、検査キット
EP1817588B1 (en) Lateral-flow test device providing improved test result validity
US20100075440A1 (en) Assay method
JP5011244B2 (ja) 被験物質の検出方法
WO2023008129A1 (ja) 検査用カートリッジ
WO2023008128A1 (ja) 検査用カートリッジ
WO2022202262A1 (ja) カートリッジ及びイムノクロマトグラフ検査装置
WO2025023049A1 (ja) イムノクロマトグラフ検査用デバイス
JP2023032867A (ja) 検査装置、およびカートリッジ
US20250208128A1 (en) Immunochromatographic cartridge
CN205176037U (zh) 一种可定量的免疫层析装置
WO2022202261A1 (ja) イムノクロマトグラフ検査装置
WO2022202378A1 (ja) 検査用カートリッジ
WO2023002842A1 (ja) イムノクロマトグラフ検査装置
WO2022202263A1 (ja) イムノクロマトグラフ検査装置
WO2022202379A1 (ja) 検査用カートリッジ
WO2022203018A1 (ja) イムノクロマトグラフ検査装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22849194

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023538386

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2022849194

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022849194

Country of ref document: EP

Effective date: 20240229